OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:55 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

NCT03510455 · National Institute of Dental and Craniofacial Research (NIDCR) · PHASE2 · terminated · last registry update 2026-11-10 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Study was stopped early due to a greater than expected incidence of ocular AEs and analysis of the data from the first 4 subjects indicating that the likelihood of permanent remission with this therapy was low.”–Registry record, National Institute of Dental and Craniofacial Research (NIDCR)

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision